BioNTech – Talk Bio

BioNTech Halts Cell Therapy Manufacturing at Maryland Site, Lays Off Dozens

2 weeks ago talkbio0Tagged BioNTech, BNT211, Cancer Therapeutic Procedure, CAR-T, Cell Therapy, Clinical Trials, Gaithersburg, layoffs, Manufacturing Facilities, Maryland (geographic location)

BioNTech; cell therapy; Maryland; layoffs; CAR-T; BNT211; Gaithersburg; manufacturing facility; cancer therapy; clinical trial

BioNTech Acquires CureVac to Advance mRNA Cancer Therapies and End Patent Disputes

2 weeks ago talkbio0Tagged Acquisition, BioNTech, biotech merger, COVID19 (disease), CureVac, Immunotherapy for cancer, Legal patent, Merger, RNA, Messenger, Vaccines

BioNTech; CureVac; mRNA; acquisition; COVID-19 vaccine; cancer immunotherapy; merger; patent dispute; biotech merger

BioNTech to Acquire CureVac in $1.25B All-Stock mRNA Deal

3 weeks ago talkbio0Tagged Acquisition, all-stock, BioNTech, Biotechnology, Cancer Therapeutic Procedure, COVID-19 Vaccines, CureVac, Germany, mRNA Vaccines, Neoplasms

BioNTech; CureVac; acquisition; mRNA vaccines; cancer treatment; all-stock deal; Germany; biotechnology; oncology; COVID-19 vaccine

Bristol Myers Squibb Commits Up to $11B+ in Major BioNTech Solid Tumor Bispecific Antibody Deal

1 month ago talkbio0Tagged Antibodies, Bispecific, BioNTech, BNT327, Immunotherapy for cancer, milestone payments, Myers, Partnership, PD-L1, Solid Neoplasm, squibb, Vascular Endothelial Growth Factor A

Bristol Myers Squibb; BioNTech; BNT327; bispecific antibody; solid tumors; PD-L1; VEGF-A; cancer immunotherapy; partnership; milestone payments

Bristol Myers Squibb Signs $11B Deal With BioNTech for Bispecific Cancer Antibody BNT327, Surpassing Recent Merck and Pfizer Moves

1 month ago talkbio0Tagged Antibodies, Bispecific, BioNTech, biotech partnerships, BNT327, immuno-oncology, Malignant Neoplasms, Myers, PD-L1, Solid Neoplasm, squibb, Vascular Endothelial Growth Factor A

Bristol Myers Squibb; BioNTech; BNT327; bispecific antibody; immuno-oncology; cancer; PD-L1; VEGF-A; solid tumors; biotech partnerships

DualityBio Pursues $200M IPO in Hong Kong Amid Volatile Market Conditions

3 months ago talkbio0Tagged Antibody-Drug, BioNTech, biotech sector, DualityBio, global trade tensions, Hong, Immunostimulating conjugate (antigen), Investments, IPO, Kong, Market, Stock exchange, upheaval

DualityBio, IPO, Hong Kong Stock Exchange, biotech investment, antibody-drug conjugates, BioNTech, market upheaval, global trade tensions, biotech sector growth.

BioNTech shows off lung cancer survival data behind phase 3 push for red-hot bispecific

3 months ago talkbio0Tagged BioNTech, BioNTech 's, BNT327, month, Pharmacotherapy, Small cell carcinoma of lung

BNT327, BioNTech, month, BioNTech ‘s, Small cell carcinoma of lung, Pharmacotherapy

FDA Pauses BioNTech’s Malaria Vaccine Trial Amid Regulatory Scrutiny

4 months ago talkbio0Tagged BioNTech, Malaria, regulatory, RNA Vaccine, Study on Hold, United States Food and Drug Administration, Vaccines

BioNTech, malaria vaccine, FDA clinical hold, RNA vaccine, regulatory challenges

BioNTech Resolves COVID-19 Vaccine Royalty Disputes with NIH and UPenn

6 months ago talkbio0Tagged Agreement, BioNTech, COVID19 (disease), Disputes, NIH Mouse, Pfizer, Royalty, settlement, UPenn, Vaccines

BioNTech, COVID-19 vaccine, royalty disputes, NIH, UPenn, Pfizer, settlement agreements

BioNTech Advances PD-L1/VEGF Bispecific Antibody with Encouraging Breast Cancer Trial Results

7 months ago talkbio0Tagged Antibodies, Bispecific, BioNTech, BNT327/PM8002, Clinical Trials, Combined Modality Therapy, Malignant neoplasm of breast, PD-L1/VEGF

BioNTech, PD-L1/VEGF Bispecific Antibody, BNT327/PM8002, Breast Cancer, Oncology Strategy, Clinical Trials, Combination Therapies